Missouri Technology Corporation

We have invested in more than 90 companies since 2016, including Pinterest, Compass, Hippo, Ro, Carta, Dutchie, Anduril, Varda Space Industries, Ghost, Front, Esusu, OKCredit, and Unqork. Additionally, through our subsidiary fund, New Slate Ventures, we have financed films, documentaries, and limited series that have been acquired by Apple, Netflix, and Disney. Based in New York City, we invest globally. Backstory Sinai Capital Partners was founded in 2017. We raised $100 million and built a talented team of young investors with offices in New York, Palo Alto, and Los Angeles. We made over 90 investments, realized 11 exits, and achieved a 1X return on our first fund within two years. In 2019, we raised $100 million for a subsidiary of Sinai Capital called New Slate Ventures, with the goal of supplying the many players in the streaming wars with independent content. Our films, series, and documentaries won Academy Award nominations, Golden Globes, Grammy’s, and Emmy’s, and were acquired by the likes of Apple, Disney, and Netflix for multiples of their cost. As a solo GP, I believe boutique, disciplined, early-stage funds with effective managers will generate the best returns for investors in this forthcoming innovation cycle. Throughout my career I’ve nurtured relationships across Silicon Valley, Wall Street, Washington DC, and Hollywood, and aim to leverage this access on behalf of the founders I support. Where to Now? We’re currently in the midst of the greatest acceleration of technological progress since 2010 and the advent of mobile/social computing. New frameworks for problem solving are emerging daily aided by artificial intelligence, CRISPR technologies, climate manipulation, and several other radical new fields previously dismissed as science fiction. When we started Sinai, the prevailing wisdom in Silicon Valley was that “hardware was hard” and that software investments provided much better risk-adjusted opportunities. That assumption is becoming less credible in the current venture capital landscape, with space exploration, brain computer interfaces, driverless electric vehicles, autonomous warfare drones, and nuclear fusion companies all appearing to be increasingly within reach, with potentially transformational impacts on civilization. Sinai’s new focus will be on these harder technical problems, as we believe this is where the majority of the value creation for this next venture cycle will emerge. While we still welcome revenue generating SaaS businesses, its become clearer to us that the best returns come from the most non-obvious ideas in undefined markets and categories. Some of our latest investments include Anduril, Varda, Galvanick, Rangeview, Factory.AI, Science.IO, and several others. We seek to invest in 5-10 companies each year, with average check sizes ranging between $1-5M depending on stage. We’re happy to lead seed rounds where we have high conviction, but prefer to collaborate with our friends at top funds across the globe. We are geographically agnostic, but are most active in New York, San Francisco, Miami, London, and the South Bay of Los Angeles.

Through its activities, Technology Ventures facilitates promising inventions to improve the quality of life for patients around the world. The mission of Technology Ventures is to promote the commercial development of Cedars‑Sinai research into products and services that advance healthcare and improve patient wellbeing. Technology Ventures actively seeks industry partners to develop these technologies and works to establish mutually beneficial long‑term relationships.

The NATO Innovation Fund (NIF) was created to supercharge the Alliance’s unique innovation ecosystems. Allied talent and research in Science, Technology, Engineering, and Mathematics (STEM) are world-leading, but the market to support deep tech innovation is underfunded. With the NIF, we are creating a commercialisation machine in both the private and public sectors, backing innovators to secure the future for the Alliance's 1 billion citizens. Focus The NIF is a standalone EUR 1 billion venture capital fund supporting ambitious founders developing emerging and disruptive technologies. For us, high-impact verticals include artificial intelligence (AI), biotechnology, energy & propulsion, manufacturing, and space. We are passionate about autonomy, hypersonics, new materials and quantum, and want to shore up cutting-edge hardware and software. Rallying around NATO’s Emerging and Disruptive Technologies (EDTs), our focus will evolve in parallel with today’s rapid innovation environment. Artificial Intelligence (AI) Autonomy Quantum Biotechnologies Hypersonic Systems Space Novel Materials & Manufacturing Energy & Propulsion Next-Generation Communications Objectives With a long-term view, the NIF enables transformative technologies with the potential to shape our security for decades to come. Our mission is an essential one, and it holds us to seeking out cutting-edge developments that solve NATO's challenges through adoption in defence and security markets; bolstering the capacities of Allied innovation ecosystems; and ultimately driving the scale and success of our portfolio.

The Hatchery, fully developed and supported by TLA, is Singapore’s leading incubator dedicated to bringing innovative ideas in the areas of Agri-Food Technology, Industrial & Synthetic Biology, as well as Human & Veterinary Sciences to the market.​ TLA is a licensed venture capital fund manager and it has the capacity to make pre-seed, seed and series A investments through The Lifesciences Innovation Fund (TLIF). Incubator Program At Temasek Life Sciences Accelerator (TLA), we aim to become the foremost “Go-To” incubator for life sciences in Singapore. To achieve our mission, we offer an attractive incubator support program to early stage companies in Singapore by providing timely and relevant market research, combined with business networking expertise to incubatees. TLA’s distinctive differentiation for its incubation program lies in its unique sectoral focus in Agri-Food Technology, Industrial & Synthetic Biology as well as Human & Veterinary Sciences. Agri-Food Technology Developing innovative solutions to improve overall productivity for food tech, enhanced urban agri and aquaculture operations. Industrial & Synthetic Biology The global market for industrial biotechnology is enormous and innovation is key for economic growth and value creation. Human & Veterinary Sciences Bringing together the know-how in vaccine, diagnostics and therapeutics to help Singapore prepare for its ageing population and potential diseases outbreak.

Bio&Tech Smart Capital is the alliance of researchers and entrepreneurs with Venture Capital management professionals to transfer scientific knowledge to society, with the aim of transforming spin off projects and startups that emerge from universities into solid and profitable companies. innovation laboratories and institutions. Investment criteria Bio&Tech Smart Capital focuses its activity focus on: Digital technologies applied to life sciences (focus on automation and data science). Biotechnology. Diagnostics and medical devices. Sustainability. Selected for the combination of: social impact, potential profitability and the experience and knowledge of the sector of the team. Diversification : no sector will represent more than 50% of the invested capital.

We invest in the innovators behind the miracles of science who are passionate about improving human health. Sanofi Ventures serves as an entry point to the innovation ecosystem for Sanofi, strategically investing in early-stage transformational science and technology, when companies are too early to partner with or acquire. Our Approach As the corporate venture capital arm of Sanofi, we invest in top-tier biotech and digital health companies that focus on helping patients and transforming the practice of medicine. We invest across all stages of the private company lifecycle, from Seed to Series B and beyond, while leading financings, serving on boards, and taking pride in working alongside portfolio companies to drive long-term value through future financings and IPO. How We Work Think of us like institutional venture capitalists with an added bonus: in addition to our investment, we aim to offer our portfolio companies select access to Sanofi’s expertise and capabilities in science, preclinical and clinical development, regulatory, data analytics, manufacturing, market access, and commercialization. Our goal is to foster strong relationships over time so when our portfolio company is ready to consider a partnership or acquisition, our colleagues on the BD and M&A teams can be a first and last call. We move quickly, we don’t believe in drawn-out processes, and we always aim to provide thoughtful feedback. Our Investment Focus We invest in early-stage biotech and digital health companies of strategic interest to Sanofi. We seek to accelerate all strategic focus while reaching into novel and emerging areas of science and technology. Here are some of the areas that we currently are thinking about: Rare diseases Immunology and inflammation Oncology Cell and gene therapy Vaccines Digital health and data science We can't do it alone - we would love to hear how we can team up to improve human health for people everywhere!